|Articles|March 1, 2004
Cohesive agent performs reliably in all stages of surgery
Cataract surgeons who choose sodium hyaluronate 1.2% (StaarVisc II, STAAR Surgical) for their routine cases know they can rely on it from beginning to end to offer all the features they seek in a viscoelastic.
Advertisement
Newsletter
Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Ophthalmology Times - Clinical Insights for Eye Specialists
1
FDA grants IDE approval to EyeYon Medical for its US clinical study of EndoArt
2
Ocular Therapeutix accelerates NDA submission plans for AXPAXLI for wet AMD
3
First patient treated in ViaLase’s IDE trial
4
Formosa Pharmaceuticals and Rxilient sign licensing and commercialization agreement for APP13007
5











































.png)


